Publications by authors named "Samuel Rosner"

Claim this Profile
A
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.
Bingnan Zhang, Laura Alder, Samuel Rosner, Aakash Desai, Alissa J Cooper

Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Pathologic complete response in a patient with simultaneous diagnoses of resectable NSCLC and myeloid neoplasm with PDGFRA rearrangement treated with concurrent neoadjuvant chemoimmunotherapy and imatinib: translating clinical trial data to real-world practice.
Chad B Sussman, Minal Shah, Kausha Amin, Rachel Fanaroff, Eric Krause, Samuel Rosner

Front Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.
Samuel Rosner, Sydney Connor, Khaled Sanber, Marianna Zahurak, Tianbei Zhang

Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?
Joshua E Reuss, Samuel Rosner, Benjamin P Levy

Clin Adv Hematol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer.
Joseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, Archana Balan, James R White, Samuel Rosner

Clin Cancer Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Brief Report on the Patterns of Mediastinal Nodal Failure in Resectable Stage IB-IIIA NSCLC Treated With Neoadjuvant Immunotherapy Combinations, a Secondary Analysis of a Prospective Trial.
Serena Mao, Samuel Rosner, Patrick M Forde, Jamie E Chaft, David R Jones

Clin Lung Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer.
Khaled Sanber, Samuel Rosner, Patrick M Forde, Kristen A Marrone

BioDrugs· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer.
Joseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, Archana Balan, James R White, Samuel Rosner

bioRxiv· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adagrasib: a novel inhibitor for -mutated non-small-cell lung cancer.
Matthew Z Guo, Kristen A Marrone, Alexander Spira, Samuel Rosner

Future Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress.
Samuel Rosner, Augusto Valdivia, Hui Jing Hoe, Joseph C Murray, Benjamin Levy

Am Soc Clin Oncol Educ Book· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer.
Samuel Rosner, Joshua E Reuss, Marianna Zahurak, Jiajia Zhang, Zhen Zeng

Clin Cancer Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapsed small-cell lung cancer: a disease of continued unmet need.
Samuel Rosner, Benjamin Levy

Lancet Respir Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-operative ctDNA monitoring in stage I colon cancer: A case report.
Stephanie L Alden, Harmeet Dhani, Charuta C Palsuledesai, Shifra Krinshpun, Adham Jurdi, Samuel Rosner

Front Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis.
Samuel Rosner, Chunnan Liu, Patrick M Forde, Chen Hu

JTO Clin Res Rep· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy.
Michael Hwang, Jenna Vanliere Canzoniero, Samuel Rosner, Guangfan Zhang, James R White

J Immunother Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC.
Samuel Rosner, Patrick M Forde

J Thorac Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study.
Samuel Rosner, Alexander I Spira

Clin Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma.
Samuel Rosner, Yuri Agrawal, Daniel Q Sun, Nafi Aygun, Megan D Schollenberger

J Immunother Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer.
Valsamo Anagnostou, Noushin Niknafs, Kristen Marrone, Daniel C Bruhm, James R White, Samuel Rosner

Nat Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series.
Jaclyn LoPiccolo, Megan D Schollenberger, Sumia Dakhil, Samuel Rosner, Osama Ali

J Immunother Cancer· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Valsamo Anagnostou, Patrick M Forde, James R White, Noushin Niknafs, Carolyn Hruban, Samuel Rosner

Cancer Res· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 Blockade in Early-Stage Lung Cancer.
Samuel Rosner, Joshua E Reuss, Patrick M Forde

Annu Rev Med· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Honoring a Patient: From Suspicion to Diagnosis.
Samuel Rosner, Emily R Insetta

Am J Med· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone.
Samuel Rosner, Filiz Sen, Michael Postow

J Immunother Cancer· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
Samuel Rosner, Erica Kwong, Alexander N Shoushtari, Claire F Friedman, Allison S Betof

Cancer Med· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis